Labcorp Holdings
Labcorp runs clinical diagnostic labs and patient-service centers across the US.
On the record
Checkpoint: Q2 2026 earnings call, watch for DOJ settlement follow-up commentary
The call
Labcorp's physical network and regulatory licensing block AI disruption, but recurring billing settlements and reimbursement pressure remain the real risks.
Labcorp runs the physical network that processes blood tests and drug screens for doctors, hospitals, and patients across America, generating about $14 billion in yearly revenue. It is hard to replace because it owns thousands of patient-service centers, has contracts locked in with insurers and Medicare, and holds regulatory licenses that take years to obtain; competitors like Quest Diagnostics face the same barriers, so neither can easily steal the other's business, and no software or AI company can simply build what Labcorp has built without the physical footprint and government approval. The one thing that could change the picture is if the U.S. government keeps cracking down on how Labcorp bills for tests (a second legal settlement just happened in July 2026 for unnecessary urine drug screening), because repeated settlements could shrink profits and invite closer regulator watching that slows growth.
Why
01
AI pressure: None apparent. AI tools like PathAI and MyLabcorp help Labcorp read pathology and explain results faster, not replace its physical testing network. Could AI do the core job? Unlikely.
02
Bigger players: Quest Diagnostics. Quest Diagnostics runs the same lab-testing duopoly, competing center-by-center and contract-by-contract for payer and hospital deals. Could a giant copy it? No, they are blocked.
03
What protects it. CLIA/FDA licensing plus roughly 2,000 patient-service centers and locked-in payer contracts are costly and slow to replicate.
What would change this call
DOJ follow-on activity or new FCA settlements after the July 15, 2026 urine-testing case. Would show regulator scrutiny escalating beyond an isolated incident.
Outcome of AMCA data-breach final approval hearing on August 20, 2026. Would show scale of liability and reputational fallout from the breach settlement.
Q2 2026 earnings (July 30, 2026) commentary on reimbursement rates and specialty-test rollout. Would show whether margin pressure or Invitae-driven growth is dominating results.
Outcome of AMCA data-breach final approval hearing on August 20, 2026. Would show scale of liability and reputational fallout from the breach settlement.
Q2 2026 earnings (July 30, 2026) commentary on reimbursement rates and specialty-test rollout. Would show whether margin pressure or Invitae-driven growth is dominating results.
Key numbers
- FY2025 revenue $13.95B, up 7.25% YoY
- >750 million tests performed worldwide in 2025
- $14.5M DOJ settlement over unnecessary drug testing
Named risks
- Recurring DOJ False Claims Act billing-practice settlements, second case July 15, 2026, inviting sustained regulator attention.
- AMCA data-breach class action overhang through final approval hearing August 20, 2026 claims deadline September 3, 2026.
- Medicare/payer reimbursement pressure on routine testing which grew only ~2.6% in H1 2024 versus specialty testing.
- Pending ERISA class action over benefits-plan administration transferred to Middle District of North Carolina, May 2026.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Quest Diagnostics | contesting | Licensed same PathAI AISight Dx platform via $100M 2024 deal, launched Google AI chatbot March 2026 |
| Sonic Healthcare USA | contesting | Part of four-lab group with only ~2.6% combined H1 2024 routine-testing growth |
| Eurofins Scientific | contesting | Global specialty and genomic testing rival competing for post-Invitae specialty share, 2025-2026 |
| Exact Sciences | gaining on | At-home screening space contested as Labcorp launched rival ColoSense nationwide in June 2026 |
Questions people ask
- Is Labcorp profitable in 2026?
- Yes. Labcorp reported FY2025 revenue of $13.95B with diluted EPS of $10.46 and free cash flow of $1.21B as of December 31, 2025, and raised FY2026 guidance to $14.7-14.8B revenue with adjusted EPS of $17.70-18.35 after a strong Q1 2026.
- Could AI replace Labcorp?
- No. Labcorp's core business relies on CLIA/FDA-licensed physical labs and a ~2,000+ patient-service-center phlebotomy network that AI cannot replicate. Labcorp instead deploys AI itself, launching the MyLabcorp app in May 2026 and nationwide PathAI digital pathology in February 2026.
- Who is Labcorp's biggest competitor?
- Quest Diagnostics is Labcorp's closest rival in the US clinical-lab duopoly. Quest licensed the same PathAI AISight Dx platform via a $100M 2024 acquisition and launched a Google-powered AI results chatbot in March 2026, matching Labcorp's AI moves.
- Is Labcorp facing legal or regulatory trouble?
- Yes. On July 15, 2026, Labcorp agreed to pay $14.5M to resolve DOJ False Claims Act allegations over medically unnecessary urine drug testing billed to Medicare from 2018-2023, its second recent billing-practices settlement after a $35M AMCA data-breach settlement pending final approval August 20, 2026.
- Is Labcorp laying off workers due to AI?
- No disclosed AI-linked layoffs exist. Labcorp's headcount grew to approximately 71,000 employees as of December 31, 2025, up about 1,000 (1.43%) year over year, even as it rolled out AI tools like MyLabcorp and PathAI's AISight Dx.
- Who owns Labcorp?
- Labcorp Holdings Inc. is a publicly traded standalone company on the NYSE under ticker LH, with a market cap of roughly $23.2B as of July 20, 2026. Adam H. Schechter serves as Chairman, President, and CEO.
Timeline
- 2026-07-15Labcorp agrees to pay $14.5M DOJ settlement over unnecessary urine drug testing billed to Medicare, 2018-2023
- 2026-05-21Deloitte & Touche LLP ratified as 2026 auditor at annual meeting
- 2026-05-20Labcorp launches MyLabcorp AI-powered patient app for lab-result interpretation
- 2026-04-29Q1 2026 revenue hits $3.54B, EPS $4.25 beats consensus; FY2026 guidance raised
- 2026-04-21Court grants preliminary approval of $35M AMCA data-breach class-action settlement
- 2026-03-19Labcorp completes acquisition of Crouse Health's Laboratory Alliance of Central New York assets
- 2026-02-17Labcorp reports FY2025 revenue of $13.95B, up 7.25% YoY
- 2025-11-20Lunit and Labcorp announce AI-powered digital pathology research collaboration
- 2024-08-05Labcorp finalizes acquisition of Invitae genetic-testing assets for ~$239M
Head to head
Revision history
20 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Labcorp Announces 2025 Fourth Quarter and Full Year Results (2026-02-17)
- Labcorp (LH) Earnings Date and Reports 2026 (2026-07-14)
- Labcorp Corporate Facts
- Labcorp Holdings (LH) Number of Employees 1994-2025 (2026-06-22)
- Labcorp Finalizes Acquisition of Select Assets of Invitae (2024-08-05)
- Labcorp Holdings (LH) Revenue 2005-2025 (2026-04-29)
- Labcorp Holdings (LH) Revenue 2005-2026 (2026-06-29)
- Labcorp joins lab results personalization push with 'MyLabcorp' AI app (2026-05-20)
- Labcorp expands use of digital pathology with renewed PathAI partnership (2026-03-02)
- Lunit and Labcorp Announce Strategic Collaboration (2025-11-20)
- Labcorp Agrees to Pay $35M to Settle AMCA Data Breach (2026-07-09)
- Labcorp Agrees to Pay $14.5 Million for Testing Fraud (2026-07-15)